검색어: hyperparatyroidisme (덴마크어 - 영어)

hyperparatyroidisme
hyperparathyroidism

sekundær hyperparatyroidisme
secondary hyperparathyroidism

ikke kendt: sekundær hyperparatyroidisme.
not known: hyperparathyroidism secondary.

ved hyperparatyroidisme producerer biskjoldbruskkirtlerne for meget
this is a condition where the parathyroid glands produce too much

ikke kendt: sekundær hyperparatyroidisme, thyroidit.
not known: hyperparathyroidism secondary, thyroiditis.

hvis de er under behandling for sekundær hyperparatyroidisme
if you are being treated for secondary hyperparathyroidism

markant hypercalcæmi kan være tegn på skjult hyperparatyroidisme.
marked hypercalcaemia may be evidence of hidden hyperparathyroidism.

tydelig hyperkalcæmi kan være et tegn på skjult hyperparatyroidisme.
marked hypercalcaemia may be evidence of hidden hyperparathyroidism.

ved primær og sekundær hyperparatyroidisme afgiver biskjoldbruskkirtlerne for meget pth.
in primary and secondary hyperparathyroidism too much pth is produced by the parathyroid glands.

ved hyperparatyroidisme, der skyldes nyresygdom, er den anbefalede startdosis til voksne 30 mg én gang dagligt.
in hyperparathyroidism caused by kidney disease, the recommended starting dose for adults is 30 mg once a day.

denne risiko er øget ved samtidig anvendelse af fluorquinoloner og hos dialysepatienter med sekundær hyperparatyroidisme samt efter nyretransplantation.
this risk is increased by concomitant use of fluoroquinolones and in patients undergoing dialysis with secondary hyperparathyroidism or after renal transplantation.

at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, der kræver dialyse for at rense blodet for affaldsstoffer.
treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.

mimpara blev desuden anvendt i en undersøgelse med 21 patienter med kræft i biskjoldbruskkirtlerne og 8 patienter med hyperparatyroidisme af anden årsag end nyresygdom.
mimpara has also been studied in 21 patients with parathyroid carcinoma and 8 patients with hyperparathyroidism not caused by kidney disease.

behandling af sekundær hyperparatyroidisme (hpt) hos patienter med slutstadium af nyresygdom (esrd) i vedligeholdelsesdialyseterapi.
treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.

behandling af sekundær hyperparatyroidisme (hpt) hos patienter med slutstadium af nyresygdom (esrd) i vedligeholdelsesdia lyseterapi.
treatment of secondary hyperparathyroidism (hpt) in patients with end-stage renal disease (esrd) on maintenance dialysis therapy.

mimpara fik kalciumindholdet i blodet til at falde med mere end 1 mg pr. dl hos 15 ud af 21 af kræftpatienterne og hos 6 ud af 8 patienter med hyperparatyroidisme af anden årsag end nyresygdom.
mimpara produced a decrease in blood calcium of more than 1 mg per dl in 15 out of 21 cancer patients and in 6 out of 8 patients with hyperparathyroidism not caused by kidney disease.

udvalget for humanmedicinske lægemidler (chmp) konkluderede, at mimpara er påvist at være effektivt til behandling af hyperparatyroidisme hos dialysepatienter med nyresygdom i sent stadium.
the committee for medicinal products for human use (chmp) concluded that mimpara effectiveness in the treatment hyperparathyroidism in dialysis patients with end stage renal disease had been shown.

selvom hyperparatyroidisme ikke blev rapporteret i ca209017, kan immunrelateret hyperparatyroidisme overvejes, især hvis det er associeret med hypofosfatæmi (rapporteret hos 6 patienter med hyperkalcæmi i dette studie).
although hyperparathyroidism was not reported in ca209017, immune-related hyperparathyroidism might be considered especially if associated with hypophosphataemia (reported in 6 hypercalcemic patients in this study).

i nogle prækliniske toksikologiske undersøgelser med hunde og rotter, men ikke aber, blev erytropoietin-terapien associeret med subklinisk knoglemarvsfibrose (knoglemarvsfibrose er en kendt komplikation ved kronisk nyresvigt hos mennesker og kan relateres til sekundær hyperparatyroidisme
in some pre-clinical toxicological studies in dogs and rats, but not in monkeys, erythropoietin therapy was associated with subclinical bone marrow fibrosis (bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors.

i nogle prækliniske toksikologiske undersøgelser med hunde og rotter, men ikke aber, blev erytropoietin- terapien associeret med subklinisk knoglemarvsfibrose (knoglemarvsfibrose er en kendt komplikation ved kronisk nyresvigt hos mennesker og kan relateres til sekundær hyperparatyroidisme eller ukendte faktorer.
in some pre-clinical toxicological studies in dogs and rats, but not in monkeys, erythropoietin therapy was associated with subclinical bone marrow fibrosis (bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors.